IOL

Attention to details can help to deliver patients consistent, quality outcomes.

There’s a new alternative to LASIK in the United States. In March of 2022, the FDA approved STAAR Surgical’s EVO/EVO+ VISIAN Implantable Collamer Lens (ICL) and Toric Implantable Collamer Lens (TICL).

Edward Hu, MD, PhD, looked at 812 toric IOLs utilized of various platforms, concluding a low total toric rotation rate at 2.1%.

Technical details, communication style key to presbyopia-correcting IOL journey.

Anushka M. Raj, BS, second year medical student at the University of Oklahoma’s Dean McGee Eye Institute, presents "Inter-Device Measurement Reliability of Angle Kappa and Angle Alpha, Devices and Instruments" during ASCRS.

The company announced the expansion of its commercial rollout of its MIGS implant to the UK

Cynthia Matossian, MD, shares her thoughts on the premium patient "experience" or "journey," emphasizing the outcomes of patient experiences.

Beginning in the 1970s, James J. Salz, MD, was part of a group of ophthalmologists who first inserted intraocular lens implants during cataract surgery.

The EVO/EVO+ Visian Implantable Collamer Lens provides visual freedom independent of contact lenses and glasses.

The injection of dexamethasone intraocular suspension 9% into the capsular bag may change the standard of care following cataract surgery.

Physicians find the Vivity lens offers their patients reduced glare, halos and increased spectacle independence.

The key factors include type, case complexity, and history of diabetic retinopathy/proliferative diabetic retinopathy.

Dr. Rishi Raj Borah, Country Director with Orbis India, discusses recent research he co-authored showing the top 3 barriers keeping families from accessing cataract treatment for their children in India.

The company this week is rolling out its Clareon family of IOLs, including Monofocal, PanOptix and Vivity options.

The company notes that the system’s design includes a small footprint, enhanced ergonomics, superior imaging, dual-pulsed laser, and advanced astigmatism management tools.

The eye care nonprofit has continually harnessed the power of innovation to reach new heights in the fight against avoidable blindness.

Proper measurement of the eye is key to predicting lens strength.

Researchers at the University of Arizona Health Sciences will use a $1.6 million National Eye Institute grant to study age-related lens cell changes that can lead to cataracts.

Research also highlights the top factors that lead to care, which can be used to improve parents' uptake of sight-saving surgery for their children.

According to investigators, patients implanted with diffractive multifocal IOLs had notable declines in the corrected distance visual acuity, distance corrected near VA, and near area of focus with aging

Striving to improve outcomes is important because of the negative effect of astigmatism on patients’ vision postoperatively.

The rate of adverse events was low in this higher risk, difficult-to-manage population of special-needs children, noted Margaret Reynolds, MD.

The new procedure eliminates the need for scleral flaps by positioning the T-shaped IOL haptics in the scleral wall.

The company will begin commercialization of the IC-8 small aperture IOL, used for cataract patients, upon successful completion of the manufacturing facility inspections and receipt of an official approval order from the FDA, which the company estimates in Q2 2022.

Lens combines diffractive multifocal and extended depth-of-focus properties.

“Real talk” on new devices gives surgeons, patients decision-making insights

Sustained-release option is deposited directly into the lenticular capsule.

Lens an option for complicated eyes, astigmatism, monovision candidates.

The company will host Innovation Week from Sept. 21-23, demonstrating new data management innovations across devices, workflow solutions and software applications.

Early experience with next-generation lens engenders positive perception.